Preservation of residual renal function in peritoneal dialysis patients: Still a dream?

Kidney International

Volumn 73, Issue 2, 2008, Pages 143-145

  Locatelli, F ^a   La Milia, V ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBILITY; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; NOTE; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

EID: 37549032499     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002694     Document Type: Note

References (17)

1. Locatelli F, Manzoni C. Treatment modalities in comparison: when do clinical differences emerge? Nephrol Dial Transplant 2000; 15(Suppl 1): 29-35.
2. Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997; 30: 366-367.
3. Eknoyan G et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019.
4. Locatelli F, Hannedouche T, Jacobson S et al. The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. J Nephrol 1999; 12: 85-88.
5. Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25: 248-255.
6. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418.
7. Fan SLS, Pile T, Punzalan S et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73: 200-206.
8. Coles GA, O'Donoghue DJ, Pritchard N et al. A controlled trial of two bicarbonate-containing dialysis fluids for CAPD: final report. Nephrol Dial Transplant 1998; 13: 3165-3171.
9. Mactier RA, Sprosen TS, Gokal R et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53: 1061-1067.
10. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution: clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20: 516-523.
11. Jones S, Holmes CJ, Krediet RT et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-1538.
12. Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004; 19: 2101-2106.
13. Rippe B, Simonsen O, Heimbürger O et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348-357.
14. Zeier M, Schwenger V, Deppisch R et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63: 298-305.
15. Szeto C-C, Chow K-M, Lam CW-K et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products: a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22: 552-559.
16. Feriani M, Kirchgessner J, La Greca G et al. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998; 54: 1731-1738.
17. Haas S, Schmitt CP, Arbeiter K et al. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 2003; 14: 2632-2638.